Nipple Aspirate Fluid Exfoliative Cytopathology and Molecular Biomarkers ― Current Role in the Management of Breast Health

Nipple Aspirate Fluid Exfoliative Cytopathology and Molecular Biomarkers: Current Role in the Management of Breast Health gives a comprehensive overview of the current and past uses of nipple aspirate fluid (NAF) in breast cancer diagnosis and risk assessment. Topics covered include: NAF collection methods analytical validity of NAF cytology the role of NAF cytology in breast cancer risk stratification molecular biomarkers found in NAF risk stratification based on molecular biomarkers in NAF the effects of therapeutic interventions on NAF cytology and biomarkers pharmacoeconomic evaluation of NAF-based risk assessment clinical validity and clinical utility of NAF cytopathology Nipple Aspirate Fluid Exfoliative Cytopathology and Molecular Biomarkers is a primer on the advances that have been made regarding NAF cytology and molecular biomarkers, discussing new innovations in the context of past discoveries. It contains indispensable information about a field of breast cancer research that investigators and clinicians alike should be aware of.

Steven Quay is the chairman, president, and CEO of Atossa Genetics, a leader in developing innovative breast health products and services. Dr Quay is board certified in Anatomic Pathology and has authored more than 130 papers on topics such as RNA interference, diagnostic imaging, oncology and biochemistry.